Biomarker sampling

OTHER2 trials

Sponsors

Pia Osterlund, Dr Robert Docking

Conditions

Acute Kidney InjuryMetastatic Colorectal Cancer

Unknown Phase

A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland

Pia OsterlundMetastatic Colorectal Cancer

Start: 2012-02-29End: 2025-12-31Target: 1000Updated: 2015-03-26

Evaluating Novel Biomarkers in Acute Kidney Injury

CompletedNCT01573104

Dr Robert DockingAcute Kidney Injury

Start: 2012-11-30End: 2015-01-31Updated: 2015-05-27

Related Papers

Relapse patterns, risk factors, re-resectability and survival after curative treatment for metastatic colorectal cancer (mCRC): A RAXO substudy.

Journal of Clinical Oncology2025-05-281 citations

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

British Journal of Cancer2022-05-2416 citations

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

2022-03-3019 citations

Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and <sup>1</sup>H-MR spectroscopy compared with histology (subgroup in the RAXO trial).

2021-07-2611 citations

Resectability, conversion and resections rates, and outcomes in <i>RAS</i>&<i>BRAF</i> wildtype (wt), <i>RAS</i> mutant (mt) and <i>BRAF</i>mt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

Journal of Clinical Oncology2021-05-202 citations

Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).

Journal of Clinical Oncology2019-05-20